Journal
RHEUMATOLOGY
Volume 59, Issue -, Pages 39-51Publisher
OXFORD UNIV PRESS
DOI: 10.1093/rheumatology/keaa381
Keywords
lupus nephritis; renal biopsy; classification; risk factors; prognosis; B cells; calcineurin inhibitors
Categories
Funding
- GSK
Ask authors/readers for more resources
Lupus nephritis (LN) is a frequent and severe manifestation of SLE. Along the decades, the epidemiology of LN and its clinical presentation have been changing. However, even though retrospective cohort studies report a decreased mortality rate and an improvement in the disease prognosis, the percentage of patients progressing into end stage renal disease (ESRD) keeps steady despite the improvements in therapeutic strategies. Current in-use medications have been available for decades now, yet over the years, regimens for optimizing their efficacy and minimizing toxicity have been developed. Therapeutic research is now moving towards the direction of precision medicine and several new drugs, targeting selectively different pathogenetic pathways, are currently under evaluation with promising results. In this review, we address the main changes and persistent unmet needs in LN management throughout the past decades, with a focus on prognosis and upcoming treatments.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available